| Wykoff, Charles C |
PRECISION, NCT04411693: Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema |
|
|
| Completed | 4 | 23 | US | Dexamethasone implant, Ozurdex, Aflibercept, Eylea | The Cleveland Clinic, Allergan | Diabetic Macular Edema | 01/24 | 01/24 | | |
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial |
|
|
| Active, not recruiting | 4 | 446 | Europe, Canada, US, RoW | Faricimab | McMaster University, Hoffmann-La Roche | Diabetic Macular Edema | 12/26 | 12/26 | | |
ARCHER II, NCT06510816: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA) |
|
|
| Recruiting | 3 | 630 | US | ANX007, Sham Administration | Annexon, Inc. | Geographic Atrophy | 10/26 | 10/27 | | |
| Completed | 3 | 410 | Europe, US, RoW | HLX04-O, ranibizumab | Shanghai Henlius Biotech | Age Related Macular Degeneration | 12/24 | 12/24 | | |
NCT06397131: A Study to Determine the Safety and Efficacy of NT-501 With MHFM |
|
|
| Not yet recruiting | 3 | 13 | US | NT-501 CNTF Implant | Neurotech Pharmaceuticals | Macular Telangiectasia Type 2 | 04/26 | 07/26 | | |
AO, NCT05904028: Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD |
|
|
| Recruiting | 3 | 600 | Canada, US | Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule, Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule, Home OCT | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation | Neovascular Age-related Macular Degeneration | 07/27 | 07/27 | | |
| Recruiting | 3 | 560 | US | Fenofibrate, Placebo | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation, Roche Pharma AG, The Leona M. and Harry B. Helmsley Charitable Trust | Diabetic Retinopathy | 04/29 | 04/29 | | |
| Active, not recruiting | 2 | 60 | Europe, US | Serine, Fenofibrate | The Lowy Medical Research Institute Limited | Macular Telangiectasia Type 2 | 03/24 | 03/24 | | |
NCT05532735: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion |
|
|
| Completed | 2 | 16 | US | ANXV | Annexin Pharmaceuticals AB, InFocus Clinical Research | Retinal Vein Occlusion | 07/24 | 11/24 | | |
CAPE, NCT05512962: Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema |
|
|
| Completed | 2 | 25 | US | Triamcinolone Acetonide, Triesence®, Semi-automated Suprachoroidal Microcatheter, Oxulumis® | Oxular Limited | Diabetic Macular Edema | 11/23 | 11/23 | | |
NCT05573100: The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME) |
|
|
| Completed | 2 | 67 | US | CU06-1004, SAC-1004, CU06, CU06-RE | Curacle Co., Ltd., Théa Open Innovation, France | Diabetic Macular Edema | 05/23 | 06/23 | | |
GION, NCT06178055: A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) |
|
|
| Active, not recruiting | 2 | 75 | US | KUS121 high dose, KUS121 low dose, Sham procedure | Kyoto Drug Discovery and Development Co., Ltd. | Central Retinal Artery Occlusion | 03/25 | 12/25 | | |
OXEYE, NCT05697809: Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema |
|
|
| Active, not recruiting | 2 | 3 | US | OXU-001, DEXAspheres®, Semi-automated suprachoroidal illuminated microcatheter, Oxulumis®, Ozurdex® Ophthalmic Intravitreal Implant, intravitreal dexamethasone implant | Oxular Limited | Diabetic Macular Edema | 11/24 | 03/25 | | |
| Active, not recruiting | 2 | 128 | US | Tonabersat, Placebo | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation | Diabetic Macular Edema | 06/25 | 11/25 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
| Active, not recruiting | 2 | 179 | US | Faricimab | Greater Houston Retina Research, Genentech, Inc. | Non-Proliferative Diabetic Retinopathy | 03/26 | 04/26 | | |
NCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 146 | Europe, US, RoW | Iptacopan (LNP023), Placebo | Novartis Pharmaceuticals | Age-Related Macular Degeneration | 10/26 | 10/26 | | |
| Not yet recruiting | 1/2 | 20 | US | SC CLS-TA, IVT Aflibercept, Eylea | Greater Houston Retina Research, Clearside Biomedical, Inc. | Diabetic Macular Edema | 09/17 | | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
| Recruiting | 1/2 | 63 | US | OCU410 | Ocugen | Geographic Atrophy | 09/25 | 09/25 | | |
| Recruiting | 1/2 | 42 | US | OCU410ST | Ocugen | Stargardt Disease | 10/25 | 10/25 | | |
NCT05986864: Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) |
|
|
| Recruiting | 1/2 | 68 | US, RoW | SKG0106 | Skyline Therapeutics (US) Inc. | Neovascular Age-related Macular Degeneration | 01/26 | 01/26 | | |
NCT05345769: Safety and Efficacy of AM712 in Patients with NAMD |
|
|
| Completed | 1 | 21 | US | AM712(ASKG712) | AffaMed Therapeutics Limited | Neovascular Age-related Macular Degeneration | 11/24 | 11/24 | | |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
RBBK, NCT06796673: Retina BioBank: Retina Biomarkers for a Deeper Understanding of Vitreoretinal and Systemic Diseases |
|
|
| Enrolling by invitation | N/A | 10000 | US | | Greater Houston Retina Research | Other Retinal Disorders, Retinal Disease, Retinal Vascular Disorder | 04/32 | 08/32 | | |
| Recruiting | N/A | 400 | US | Immediate Vitrectomy, Deferred Vitrectomy | Jaeb Center for Health Research, National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation | Epiretinal Membrane | 12/26 | 12/26 | | |
| Not yet recruiting | N/A | 150 | NA | | Greater Houston Retina Research | Diabetic Retinopathy, Diabetic Macular Edema, Other Retinal Disorders | 04/23 | 08/23 | | |
| Cormier, Jessica |
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) |
|
|
| Recruiting | 3 | 360 | Europe, US, RoW | Elamipretide, Elamipretide HCL, Placebo | Stealth BioTherapeutics Inc. | Age Related Macular Degeneration (ARMD) | 08/26 | 08/27 | | |
Spectra, NCT05393284: Phase 2 Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy |
|
|
| Active, not recruiting | 2 | 114 | US | OPL-0401 Dose 1, Placebo | Valo Health, Inc. | Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy | 08/24 | 08/24 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
| McDonald-Mueller, Lauren |
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 1 | 42 | US | OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212 | Olix Pharmaceuticals, Inc., Trial Runners, LLC | Neovascular Age-related Macular Degeneration | 11/24 | 12/24 | | |
